These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22277276)

  • 1. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy.
    Demizu Y; Okuhira K; Motoi H; Ohno A; Shoda T; Fukuhara K; Okuda H; Naito M; Kurihara M
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1793-6. PubMed ID: 22277276
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
    Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
    J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Design, Synthesis, and Evaluation of SNIPER(ER) That Induces Proteasomal Degradation of ERα.
    Okuhira K; Demizu Y; Hattori T; Ohoka N; Shibata N; Kurihara M; Naito M
    Methods Mol Biol; 2016; 1366():549-560. PubMed ID: 26585163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.
    Itoh Y; Ishikawa M; Naito M; Hashimoto Y
    J Am Chem Soc; 2010 Apr; 132(16):5820-6. PubMed ID: 20369832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein.
    Okuhira K; Ohoka N; Sai K; Nishimaki-Mogami T; Itoh Y; Ishikawa M; Hashimoto Y; Naito M
    FEBS Lett; 2011 Apr; 585(8):1147-52. PubMed ID: 21414315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.
    Itoh Y; Kitaguchi R; Ishikawa M; Naito M; Hashimoto Y
    Bioorg Med Chem; 2011 Nov; 19(22):6768-78. PubMed ID: 22014751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a peptide-based inducer of nuclear receptors degradation.
    Demizu Y; Ohoka N; Nagakubo T; Yamashita H; Misawa T; Okuhira K; Naito M; Kurihara M
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2655-8. PubMed ID: 27086122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecules destabilize cIAP1 by activating auto-ubiquitylation.
    Sekine K; Takubo K; Kikuchi R; Nishimoto M; Kitagawa M; Abe F; Nishikawa K; Tsuruo T; Naito M
    J Biol Chem; 2008 Apr; 283(14):8961-8. PubMed ID: 18230607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of inhibiting the proteasomal degradation of estrogen receptor alpha on estrogen receptor alpha activation under hypoxic conditions.
    Park YM; Cho JY; Koo YD; Lee YJ
    Biol Pharm Bull; 2009 Dec; 32(12):2057-60. PubMed ID: 19952428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
    Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
    Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of peptide-based chimeric molecules to induce degradation of the estrogen and androgen receptors.
    Yokoo H; Ohoka N; Naito M; Demizu Y
    Bioorg Med Chem; 2020 Aug; 28(15):115595. PubMed ID: 32631565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
    Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors.
    Masuyama H; Hiramatsu Y
    J Biol Chem; 2004 Mar; 279(13):12020-6. PubMed ID: 14702340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.